<DOC>
	<DOCNO>NCT02684032</DOCNO>
	<brief_summary>This multicenter , open label , Phase 1b study patient mBC . This study dose escalation identify maximum tolerate dose ( MTD ) combination gedatolisib plus palbociclib/fulvestrant gedatolisib plus palbociclib/letrozole expansion estimate objective response rate ( OR ) combination gedatolisib plus palbociclib/letrozole palbociclib/fulvestrant .</brief_summary>
	<brief_title>A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>This multicenter , open label , continuous Phase 1b study patient MBC . This study dose escalation expansion . The dose escalation identify maximum tolerate dose ( MTD ) combination gedatolisib plus palbociclib/fulvestrant gedatolisib plus palbociclib/letrozole . The expansion estimate objective response rate ( OR ) combination gedatolisib plus palbociclib/letrozole combination gedatolisib plus palbociclib/fulvestrant .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Women 18 year age old , either : Postmenopausal Pre/perimenopausal woman medicallyinduced menopause treatment agent induce chemical menopause . Histologically cytologically proven diagnosis breast cancer evidence metastasis . Documentation estrogen receptor positive ( ( ER+ ) , human epidermal growth factor receptor 2 ( HER2 negative ( HER2 ) ) tumor . Dose Escalation Portion : Patients must satisfy one follow criterion : Letrozole combination cohort ( L ) : metastatic breast cancer ( MBC ) progression candidate letrozolecontaining regimen , palbociclib . Fulvestrant combination cohort ( F ) : MBC progression candidate fulvestrant contain regimen , palbociclib . Dose Expansion Portion : Patients must satisfy one follow criterion : Arm A : MBC progression prior endocrine base systemic therapy metastatic setting ; Arm B : MBC progression follow one prior endocrine base systemic therapy metastatic setting , prior therapy cyclindependent kinase ( CDK ) inhibitor ; Arm C : MBC progression follow one two prior endocrine base systemic therapy metastatic setting , follow prior therapy CDK inhibitor . Measurable disease define Response Evaluation Criteria In Solid Tumors ( RECIST ) version 1.1 . Bone patient dose escalation portion . Availability archival tumor biopsy sample willing provide fresh biopsy available . Eastern Cooperative Oncology Group [ ECOG ] performance must 0 1 . Adequate bone marrow , renal liver function . Prior treatment mechanistic target rapamycin ( mTOR ) inhibitor phosphoinositide 3kinase ( PI3K ) inhibitor . More 1 line prior chemotherapy treatment metastatic locally advanced/recurrent disease . Bone patient expansion/efficacy portion . Patients advanced/metastatic disease symptomatic visceral spread , life threaten complication need immediate therapy , massive uncontrolled effusion [ pleural , pericardial , peritoneal ] , pulmonary lymphangitis , 50 % liver replacement tumor . Known active uncontrolled symptomatic Central Nervous System ( CNS ) metastases . Active bacterial , fungal viral infection . Uncontrolled significant cardiovascular disease . Radiation therapy within 4 week investigational product . Cytotoxic chemotherapy within 4 week investigational product ( 6 week mitomycin C nitrosoureas ) immediate prior regimen administer every 3 4 week schedule 2 week investigational product immediate prior regimen consist weekly therapy . Any anti cancer agent ( eg , hormonal , biological , investigational ) within 5 time half life prior investigational product . Impairment gastro intestinal ( GI ) function GI disease . Pregnant female patient ; breastfeed female patient ; female patient childbearing potential unwilling unable use 2 highly effective method contraception outline protocol duration study 90 day .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PI3K ( phosphoinositide 3-kinase )</keyword>
	<keyword>mTOR ( mechanistic target rapamycin )</keyword>
	<keyword>PI3K/mTOR</keyword>
	<keyword>metastatic breast cancer ( MBC )</keyword>
	<keyword>ER+ ( estrogen receptor positive )</keyword>
	<keyword>HER2- ( human epidermal growth factor receptor 2 negative )</keyword>
</DOC>